To recover your password please fill in your email address
Please fill in below form to create an account with us
INTEGRATE II is a phase III international multi-centre clinical trial to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma.
See ANZCTR for full trial details >
|
Trial Summary: |
The aim of the study is to further examine the findings of the previous INTEGRATE clinical trial. The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC). |
|
Supported By: |
AGITG |
|
Eligibility: |
Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer |
|
Registration ID: |
ACTRN12616000420448 |
|
Participation: |
International |
|
Australian Lead Group: |
AGITG |
|
Status: |
Follow up |
|
Activation Date: |
23/06/2016 |
|
Chairs: |
Nick Pavlakis, David Goldstein |
|
Contact: |